FDA Approves Liraglutide (ANDA 214568) for TEVA PHARMS.

The U.S. Food and Drug Administration (FDA) granted approval for Liraglutide (ANDA 214568) to TEVA PHARMS. on August 27, 2025. This approval signifies the availability of a generic version of the drug.

Background

Liraglutide is an established medication, and this approval introduces a generic version, expanding access to the drug. The approval was issued for Abbreviated New Drug Application (ANDA) 214568.

What this means

The FDA's approval of a generic version of Liraglutide for TEVA PHARMS. is expected to increase market competition and potentially improve patient access to this important medication. Generic approvals typically lead to more affordable treatment options for patients.

Source

The information regarding this approval was sourced from the U.S. Food and Drug Administration (FDA) website, specifically the Approved Drug Products database (ANDA 214568), on August 27, 2025, available at accessdata.fda.gov.